ALSO NOTED: Bavarian Nordic, GSK drop vaccine pact; UCB preps for FDA meeting; Lilly and Shionogi in co-development deal; and m

> Bavarian Nordic and GlaxoSmithKline have dropped their agreement to jointly market Imvamune, a smallpox vaccine now in development. When the deal was signed in 2004 Bavarian Nordic didn't have the production capacity needed but says it can commercialize the therapy now on its own. Report [1]

> Responding to rumors of pipeline trouble, UCB [2] says it will meet with the FDA soon to discuss the agency's questions regarding its marketing application for the Crohn's drug Cimzia. Report [3]

> Shionogi and Eli Lilly Japan have agreed to co-develop and co-market the antidepressant duloxetine hydrochloride in Japan. Release [4]

> Molecular Insight Pharmaceuticals has priced its IPO at $14 a share after originally giving a range of $14 to $16. Report [5]

> Adnexus Therapeutics has issued "encouraging" Phase I results for its cancer therapy CT-322. Release [6]

And Finally... A new study indicates that persuading women to volunteer for clinical trials will depend a great deal on a researcher's ability to gain their trust that the trial will be conducted ethically and with their best interests in mind. Release [7]